In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs

jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 3915] ubZ fnYyh] lkseokj] fnlEcj 18] 2017@vxzgk;.k 27] 1939 No. 3915] NEW DELHI, MONDAY, DECEMBER 18, 2017/ AGRAHAYANA 27, 1939 jlk;u vkSj moZjd ea=ky; ¼vkS’k/k foHkkx½ ¼jk’Vªh; vkS’k/k ewY; fu/kkZj.k izkf/kdj.k½ vkns'k ubZ fnYyh] 18 fnlEcj] 2017 dk-vk- 3913¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 701¼v½] rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 4] 6] 10] 11] 14] 16] 17 vkSj 18 }kjk iznRr 'kfDr;ks a dk iz;kxs djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftls laf{kIr :i l s ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LrHa k ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LrHa k ¼3½ vkSj ¼4½ esa Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LrHa k ¼2½ esa dh rRLFkkuh izfof’V esa fofufnZ’V vuqlfwpr fofufeZfr;ksa esa ls izR;ds dh] oLrq ,oa lsok dj] ;fn dkbs Z gS] dks NksMd+ j vf/kdre dher ds :i eas fu;r djrh gS% lkj.kh Ø- l-a vuqlfwpr fofufeZfr dk uke [kqjkd :i ,oa izcyrk bdkbZ vf/kdre dher ¼#-½ ¼1½ ¼2½ ¼3½ ¼4½ ¼5½ 1- ,Va h&Mh bEequkXs ykcs qfyu bta Ds “ku 150 ,elhth izfr okW;y 1509-69 uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klfwpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gk½sa ls vf/kd dher ij vuqlfwpr fofufeZfr;ksa ds czkMa sM ;k tus fsjd ;k nksuksa :ikarjksa dks cps jgs vuqlfwpr fofufeZfr;ks a ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LrHa k ¼5½ esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gks½a ls vf/kd lHkh ,slh fofufeZfr;ksa dh dher dk v/kkes q[kh iqujh{k.k djsaxAs 7216 GI/2017 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼[k½ lHkh ekStnw k fuekZrkvk sa dks mi;qZDr dfFkr vuqlfwpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh d s LrHa k ¼5½ esa fofufnZ"V vf/kdre dher oLrq ,oa lsok dj lfgr ls de gS rk]s tgka dgh Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 13¼2½ ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LrHa k ¼5½ esa of.kZr vf/kdre dher ij ljdkj dks okLro eas Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM + ldr s gSAa ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvkas dks mi;qZDr lkj.kh ds LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlfwpr fofufeZfr;ksa ds iSdks a d s fy, vf/kdre dher fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V eas vf/klpw uk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dk s ,d eYw ; lpw h tkjh djsa rFkk mldh dkWih jkT; vkS"kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djAsa ¼M½+ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjk 24 ¼4½ ds mic/a kksa ds vuqlkj izR;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjkcs kj dks bl izdkj fd;k tk jgk gS fd mlls ijke“kZ ds bPNqd fdlh O;fDr d s fy, igqpa vklku gks] ogka mld s fdlh lgtn`“; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dks lia znf“kZr djxs kA ¼p½ mi;qZDr lkj.kh e sa ;Fkk fofufnZ"V [kqnjk ;k izcyrk ;k nkus k sa ds lkFk vuqlfwpr fofufefZr dk dkbs Z ekStnw k fofuekZrk vkS’k/k ewY; fu;a=.k vkn“s k] 2013 ds iSjk 2¼;½w ds vuqlkj dkbs Z ubZ vkS’kf/k dks ykpa djrk gS rks ,ls s ekStnw k fofuekZrk dh vkS’k/k ¼eYw ; fu;a=.k½ vkn's k 2013 dh vuqlpw h&II ds varxZr ;Fkk fofufnZ’V QkeZ&I eas ,uihih, dks ,slh ub Z vkS’kf/k ds iwoZ ewY; vuqeksnu gsrq vkosnu djuk gkxs kA ¼N½ mi;qZDr vuqlfwpr fofufeZfr;ks a dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lpw h II ds QkWe Z III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjikVs Z izLrqr djxs kA mi;qZDr vuqlfwpr fofufeZfr;ksa ds fuekZ.k dks dkbs Z fuekZrk mRiknu cUn djus dk bPNdq gks rks bldh lpw uk ,uihih, dks voxr djk;xs kA blds lEcU/k esa vxj vuqlfwpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rk s cUn dju s dh frfFk ls N% eghus igys lwph II ds QkeW Z IV eas Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijkDs r dfFkr lkj.kh esa n'kk;Z s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gS a rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxAs ¼>½ bl vkn's k esa mijkDs r lkj.kh ds LrHa k ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdks a dh vf/kdre dher fu;r gkus s d s ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dkbs Z gks] tks fd bl vkns'k ls iwo Z tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxAs [dk-a l-a@183@51@2017@,Q@Qk- l-a 8¼51½@2017@Mhih@,uihih,&fMoh-II] cythr flga ] lgk;d fun's kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 18th December, 2017 S.O. 3913(E).—In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. No. Name of the Scheduled Formulation Dosage form & Strength Unit Ceiling Price (Rs.) (1) (2) (3) (4) (5) 1. Anti-D Immunoglobulin Injection 150mcg Each Vial 1509.69 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/183/51/2017/F/F. No. 8(51)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vkns'k ubZ fnYyh] 18 fnlEcj] 2017 dk-vk- 3914¼v½.—;r% vkS’k/k foHkkx ¼ftls ckn esa Mhvksih ds :i esa lna fHkZr fd;k gS½ us vfuok;Z vkS’kf/k dh l'a kkfs/kr jk’Vªh; lpw h] 2015 ¼ftls ckn esa ,u,ybZ,e d s :i esa lna fHkZr fd;k gS½ ds vk/kkj ij fnukda 10-03-2016 ds dk-vk- 701¼v½ ds }kjk vkS’k/k ewY; fu;a=.k vkn's k] 2013 ¼ftls ckn esa Mhihlhvks ds :i eas lna fHkZr fd;k gS½ dh vuqlpw h I d s vk/kkj ij l'a kk/s ku fd;k gSA vkSj 02- tcfd vuqlfwpr fofufeZfr;ksa dh lpw h ds l'a kk/s ku gksus ij Mhihlhvk]s 2013 ds iSjk 17 esa la'kk/s ku dh rkjh[k ls lkB fnuks a dh vof/k ds Hkhrj Mhihlhvks] 2013 d s mic/a kksa ds vuqlkj r; gksu s okyh vuqlpw h&I eas tksM+h xbZ fofufeZfr;ksa ¼;kuh nokb;k½a dh vf/kdre dherksa dk fu/kkZj.k vko';d gSA vkSj 03- tcfd jk’Vªh; vkS’k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftls ckn esa ,uihih, ds :i esa lna fHkZr fd;k gS½ us ekpZ] 2016 e sa vf/kdre ewY; fu/kkZj.k dh izfØ;k 'kq: dh FkhA bl lca /a k e]sa ,uihih, u s fnukda 04-04-2016 ds dk;kZy; Kkiu ¼;kfu vks,e½ 19¼697½@2016@Mh II@,uihih, }kjk vuqlfwpr fofufeZfr;ksa dh ,d lpw h viyksM dh Fkh ftld s fy, eYw ; fu/kkZj.k d s fy, visf{kr MkVk vk/kkfjr lna HkZ foi.ku miyc/k ugha FkkA rnqijkar dfFkr lwph l'a kkfs/kr dh xbZ vkSj bls fnukda 28-04-2016] 13-05-2016] 10-01-2017 vkSj 08-07-2017 dks iqu% iznf'kZr fd;k x;kA mi;qZDr vks,e dh izfr;ka MªXl eSU;qQSDpjlZ ,lksfl;'s kUl dk s ;g vuqjk/s k djr s Hkts h xbZ Fkh fd os foi.ku vk/kkfjr MkVk izLrqr djsa vkSj tcfd ,uihih, us vkS’k/k foHkkx dks Mhihlhvks] 2013 dks l'a kkfs/kr djus dk Hkh lq>ko fn;k Fkk rkfd tgka foi.ku vk/kkfjr vkda M+s vf/kdre ewY; fu/kkZj.k d s fy, miyC/k ugha gSa vkSj ,slh vuqlfwpr fofufeZfr;ksa ds fy, jkT; laLFkkxr [kjhn eYw ; miyC/k gS]a mudk ewY; fu/kkZj.k gsrq lqfo/kk vuqlkj fopkj fd;k tk ldAs vkSj 04- tcfd fofuekZrkvks a vkSj vkf/kdkfjd vkda M+ s laxzg dju s okyh ,tsalh tSls ,vkbvZ kslhMh ,MCY;,w lh,l ls miyC/k djkbZ xbZ tkudkjh d s vk/kkj ij dfri; vuqlfwpr fofufeZfr;ksa ds lca /a k esa tgka foi.ku vk/kkfjr dhersa miyC/k Fkh] ,uihih, us ,slh vuqlfwpr fofufeZfr;ksa dh vf/kdre dher r; dj nh gSA ,uihih, us vc rd miyC/k vkda M+ksa d s vk/kkj ij 849 fofufeZfr;ksa dh vf/kdre dherksa dks r; dj fy;k gSA gkykfad] izklfaxd vkSj fo'oluh; foi.ku vk/kkfjr MsVk izkIr djus ds dbZ iz;klksa ds ckn Hkh] ,uihih, vko';d foi.ku MVs k dh deh d s fy, 'k’s k vuqlfwpr fofufeZfr;ksa dh vf/kdre dherksa dk fu/kkZj.k ugha dj ik;k gSA vkSj 05- tcfd ;g Mhihlhvk]s 2013 ds vuqlpw h I ds rgr vf/klfwpr lHkh nokvksa dh vf/kdre dherkas dks l'a kkfs/kr djus ds fy, ,uihih, d s fy, tufgrk sa dh j{kk ds fy,] eYw ; fu/kkZj.k d s oSdfYid rjhdks a dk s viukuk vfuok;Z gS] rkfd vko';d nokb;ksa ds miHkkDs rkvksa dks mi;qDr vkSj mfpr vf/kdre dherksa dk ykHk lqfuf'pr fd;k tk ldAs vkSj 06- tcfd ,uihih, us dnsa z ljdkj vkSj jkT;k sa vkSj jkT; fpfdRlk los k fu;e ds rgr fofHkUu ljdkjh [kjhn ,tfsal;ksa l s tkudkjh ekaxh] D;kfsad vuqlfwpr fofufeZfr;ksa dh vf/kdre dher r; djuk vko';d gSA rnuqlkj] ,vkbZvkslhMh,MCY;,w lh,l dh QkekZVªds fjikVs Z esa izklfaxd foi.ku vk/kkfjr vkda M+ksa ds vHkko eas fnukda 19-09-2017 dks ,uihih, esa vk;kfstr izkf/kdj.k dh cSBd esa r; fd;k x;k gS rkfd 'k’s k vuqlfwpr fofufeZfr;ksa dh vf/kdre dher] fofHkUu ljdkjh [kjhn ,tfsal;ksa dh [kjhn ewY;ksa ds vk/kkj ij r; dh tk,A vkSj 07- vc Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 vkSj dk-vk- 701¼v½] rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vk"Sk/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 19 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, tks ekuuh; mPp U;k;ky; vkSj Hkkjr ds ekuuh; mPpre U;k;ky; }kjk cjdjkj¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 j[kk x;k gS vkSj Hkkjr ljdkj esa jlk;u ,oa moZjd ea=ky; ¼jk’Vªh; vkS’k/k ewY; fu/kkZj.k izkf/kdj.k½ ds dk-vk- 2061¼v½] fnukda 30 tuw ] 2017 vkSj dk-vk- 2060¼v½ vkSj 2061¼v½ fnukda 30 twu] 2017 d s vkn's k ds vf/kØe.k esa tgk a rd mldk lca /a k uhps dh lkj.kh d s fofufeZfr iSd l s gS] mu ckrk sa d s flok; vf/kØkUr djrs gq, ftUgsa ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk’Vªh; vkS’k/k ewY; fu/kkZj.k izkf/kdj.k uhps dh lkj.kh d s LrHa k ¼5½ esa fofufnZ’V vf/kdre dher dks mDr lkj.kh ds LrHa k ¼3½ vkSj ¼4½ eas Øe'k% rRLFkkuh izfof’V;ksa esa fofufnZ’V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LrHa k ¼2½ e as dh rRLFkkuh izfof’V esa fofufn’Z V vuqlfwpr fofufeZfr;ksa esa ls izR;ds dh] oLrq ,oa lsok dj] ;fn dkbs Z gS] dks NksMd+ j vf/kdre dher ds :i esa fu;r djrh gS%& lkj.kh Ø- l-a vuqlfwpr fofufeZfr dk uke [kqjkd :i ,oa izcyrk bdkbZ vf/kdre dher ¼#-½ ¼1½ ¼2½ ¼3½ ¼4½ ¼5½ 1- Qus hysQjkbu MªkIsl 5% 1 fefy- 3-38 uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klfwpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gk½sa ls vf/kd dher ij vuqlfwpr fofufeZfr;ksa ds czkMa sM ;k tus fsjd ;k nksuksa :ikarjksa dks cps jgs vuqlfwpr fofufeZfr;ks a ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LrHa k ¼5½ esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gks½a ls vf/kd lHkh ,slh fofufeZfr;ksa dh dher dk v/kkes q[kh iqujh{k.k djsaxAs ¼[k½ lHkh ekStnw k fuekZrkvksa dks mi;qZDr dfFkr vuqlfwpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh d s LrHa k ¼5½ esa fofufnZ"V vf/kdre dher oLrq ,oa lsok dj lfgr ls de gS rk]s tgka dgh Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 13¼2½ ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LrHa k ¼5½ esa of.kZr vf/kdre dher ij ljdkj dks okLro eas Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM + ldr s gSAa ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvkas dks mi;qZDr lkj.kh ds LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlfwpr fofufeZfr;ksa ds iSdks a d s fy, vf/kdre dher fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V eas vf/klpw uk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dk s ,d eYw ; lpw h tkjh djsa rFkk mldh dkWih jkT; vkS’kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djAsa ¼M½+ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjk 24 ¼4½ ds mic/a kksa ds vuqlkj izR;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i es a ,sls ifjlj] tgka dkjkcs kj dks bl izdkj fd;k tk jgk gS fd mll s ijke'kZ ds bPNqd fdlh O;fDr ds fy, igqpa vklku gks] ogka mlds fdlh lgtn`'; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dks lia znf'kZr djxs kA ¼p½ mi;qZDr lkj.kh ds LrHa k ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlfwpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk l s fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykpa djrk g S rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 d s iSjkxzkQ 2¼;½w d s vuqlkj vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s rgr lpw h II esa fofufnZ"V QkeZ I d s ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkons u djuk gksxkA ¼N½ mi;qZDr vuqlfwpr fofufeZfr;ks a dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lpw h II ds QkWe Z III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjikVs Z izLrqr djxs kA mi;qZDr vuqlfwpr fofufeZfr;ksa ds fuekZ.k dks dkbs Z fuekZrk mRiknu cUn djus dk bPNdq gks rks bldh lpw uk ,uihih, dks voxr djk;xs kA blds lEcU/k esa vxj vuqlfwpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rk s cUn dju s dh frfFk ls N% eghus igys lwph II ds QkeW Z IV eas Hkjdj ,uihih, dks izLrqr djsxkA6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijkDs r dfFkr lkj.kh esa n'kk;Z s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gS a rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxAs ¼>½ bl vkn's k esa mijkDs r lkj.kh ds LrHa k ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdks a dh vf/kdre dher fu;r gkus s d s ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dkbs Z gks] tks fd bl vkns'k ls iwo Z tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxAs [dk-a l-a@183@51@2017@,Q@ Qk- l-a 8¼51½@2017@Mhih@,uihih,&fMoh-II] cythr flga ] lgk;d fun's kd ORDER New Delhi, the 18th December, 2017 S.O. 3914(E).—Whereas, the Department of Pharmaceuticals (hereinafter referred as DOP) has amended Schedule I of the Drugs Price Control Order (hereinafter referred as DPCO) 2013 vide S.O. 701(E) dated 10.03.2016 based on revised National List of Essential Medicine (hereinafter referred as NLEM) 2015; and 02. Whereas on amendment of the list of scheduled formulations, paragraph 17 of the DPCO 2013 requires fixation of the ceiling prices of formulations (i.e. medicines) added in the Schedule I to be fixed as per the provisions of the DPCO, 2013 within a period of sixty days from the date of amendment; and 03. Whereas the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) initiated the process of the ceiling price fixation in March 2016. In this connection, NPPA vide Office Memorandum (i.e. OM) 19(697)/2016/Div II/NPPA dated 4.4.2016 had uploaded a list of the scheduled formulations for which reference market based data required for price fixation was not available. The said list was subsequently amended and displayed again vide OMs dated 28.4.2016, 13.5.2016, 10.1.2017 and 8.7.2017. Copies of the aforesaid OMs were also sent to Drugs Manufacturers Associations requesting for submission of market based data and whereas NPPA had also suggested the Department of Pharmaceuticals to amend DPCO 2013 so as to facilitate consideration of the State Institutional Procurement Price for such scheduled formulations where market based data are not available to facilitate ceiling price fixation; and 04. Whereas on the basis of inputs from the manufacturer and official data collection agency viz AIOCD AWACS in respect of certain scheduled formulations where market based prices could be traced, NPPA has fixed the ceiling prices of such scheduled formulations. NPPA has so far fixed the ceiling prices of 849 formulations on the basis of available data. However, even after a number of attempts made to obtain the relevant and reliable market based data, NPPA has not been able to fix the ceiling prices of remaining scheduled formulation for the want of requisite market data; and 05. Whereas, it is obligatory on the part of the NPPA to revise the ceiling prices of all the drugs notified under the Schedule I of DPCO, 2013 so as to ensure the benefit of fair and reasonable ceiling prices to the consumers of such essential medicines to protect public interest, there is a necessity to adopt alternative methods of price fixation; and 06. Whereas NPPA also sought information from the various Government Procurement Agencies under Central Government and States and State Medical Services Corporation, as it is necessary to fix ceiling prices of scheduled formulations. Accordingly, in the absence of the relevant market based data in the Pharmatrac report of AIOCD- AWACS, it has been decided in the Authority Meeting held in the NPPA on 19/9/2017 to fix the ceiling prices of remaining scheduled formulations on the basis of procurement prices; and 07. Now, in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, which has been upheld by the Honourable High Court and also Hon’ble Supreme court of India and in supersession of the Order of the Government of India in the Ministry of¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7 Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S. O. 2060(E) and S.O. 2061(E) dated 30th June, 2017, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. No. Name of the Scheduled Formulation Dosage form & Strength Unit Ceiling Price (Rs.) (1) (2) (3) (4) (5) 1. Phenylephrine Drops 5% 1 ML 3.38 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/183/51/2017/F /F. No. 8(51)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vkns'k ubZ fnYyh] 18 fnlca j] 2017 dk-vk- 3915.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 701¼v½] rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LrHa k ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LrHa k ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;fwuV½ vkSj fofuekZrk vkSj foi.ku dEifu;kas ds uke lfgr LrHa k ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;ds dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksMd+ j vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh Ø- vuqlwfpr fofufeZfr dk izcyrk bdkbZ fofuekZrk vkSj foi.ku [kqnjk la- uke@czkaM dk uke daiuh ewY; ¼#-½ ¼1½ ¼2½ ¼3½ ¼4½ ¼5½ ¼6½ 1- Qsjl ,LdkWcVsZ $ Qkfsyd iRz ;ds fQYe fyfir xkys h e sa % 1 xkys h eSll Z fr:ifr efsMd;s j 3-63 ,flV $ l;kukds kcs kykekbu Qsjl ,LdkWcVsZ d s cjkcj ,yheus Vy fy-@eSll Z Qkbtj fy- $ ftda lYQVs ekus kgs kbMªVs vk;ju 100 fexzk- Qksfyd ,flV 1- xkys h ¼vkWfVªu&,DlVh½ 5fexzk] l;kukds kcs kykekbu 15 ,elhth] ftda lYQVs ekus kgs kbMªVs d s cjkcj ,yheus Vy ftda 22-5 fexzk- 2- jkts qoklVkfVu $ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z ,vkus QkE;yZq 's ku 13-37 dSIlyw ¼jkts Ms s lhoh 10½ jkts qoklVkfVu dfSY'k;e ds cjkcj izk- fy-@eSll Z ;,w loh jkts qoklVkfVu 10 fexzk- ¼xzkuqysl e½sa] izk- fy- DyksfiMkxs zys fclYQVs d s cjkcj DyksfiMkxs zys 75 fexzk- ¼iRz ;sd fQYe fyfir xkys h e½sa 3- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z lus VkSj 10-87 xkys h ¼Vus 20 ,e 1000½ e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl izk- fy- gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 @eSll Z Xyus ekd Z fexzk-] QkekZL;wfVdYl fy- eVs QksfeZu ,plh,y 1000 fexzk ¼,DlVMsa Ms jhfyt e½sa 4- Dykcs Vs lkys $DykfsVªektkys $ iRz ;ds xzke e%sa 1 xzke eSll Z eSudkbMa Qkek Z 2-92 U;ew kblhu lYQVs Øhe Dykcs Vs lkys izkis hvkus Vs vkbZih 0-05 fy-@ eSll Z Qkek Z Qksl Z MCY;@w MCY;]w DykfsVªektkys vkbiZ h 1-00 ycS - MCY;@w MCY; w ues kslhu lYQVs vkbiZ h 0-50% MCY;@w MCY;w 5- eksDlh¶ykWDlkflu $ iRz ;ds lLVMsa jhfyt xkys h es a % 1 xkys h eSll Z ,dEl MªXl ,Ma 33-05 lfsQDle xkys h ¼eksfDleSd ekDs lh¶ykWDlkflu gkbMZ ªksDyksjkbM chih QkekZL;wfVdYl fy-@ Iyl½ d s cjkcj eksDlh¶ykWDlkflu 400 fexzk] eSll Z eSdyvs kMs l lfsQDle vkbiZ h ¼fVªgkbMªVs d s :i e½sa QkekZL;wfVdYl fy- d s cjkcj ,gkbMZ ªksl lfsQDle 400 fexzk- 6- eksDlh¶ykWDlkflu $ iRz ;ds lLVMsa jhfyt xkys h es a % 1 xkys h eSll Z ,dEl MªXl ,Ma 33-05 lfsQDle xkys h ¼eksfDleSd ekDs lh¶ykWDlkflu gkbMZ ªksDyksjkbM chih QkekZL;wfVdYl fy-@ Iyl½ d s cjkcj eksDlh¶ykWDlkflu 400 fexzk] eSll Z eSdyvs kMs l lfsQDle vkbiZ h ¼fVªgkbMªVs d s :i e½sa QkekZL;wfVdYl fy- d s cjkcj ,gkbMZ ªksl lfsQDle 400 fexzk- 7- VªkekMkys $ iSjkflVkekys iRz ;ds fQYe fyfir xkys h e sa % 1 xkys h eSll Z ,Xa yk s Ýpsa MªXl 5-57 xkys h VªkekMkys gkbMZ ªksDyksjkbM vkbiZ h 37-5 ,Ma buMLVªht fy- fexzk-] iSjkflVkekys vkbiZ h 325 fexzk-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9 8- jkts qoklVkfVu $ ,Lizhu $ iRz ;ds fQYe fyfir ck;y;s M Z xkys h 1 xkys h eSll Z lQs Vc ykbQZ 9-97 Dykis hMkxs zys xkys h e:sa jkts qoklVkfVu dSfY'k;e vkbiZ h d s lkbal@ eSll Z buVkl cjkcj jkts qoklVkfVu 10 fexzk] ,Lizhu QkekZL;wfVdYl fy- vkbiZ h 75 fexzk Dykis hMkxs zys fclYQVs vkbiZ h d s cjkcj Dykis hMksxyzs 75 fexzk 9- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z dSfMyk 9-62 xkys h e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl fy- gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 @eSll Z lkbuZ kds es Qkek Z fexzk-] fy- eVs QksfeZu ,plh,y 500 fexzk ¼,DlVMsa Ms jhfyt e½sa 10- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z ck;kds kus fy- 10-87 xkys h e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 fexzk-] eVs QksfeZu ,plh,y 1000 fexzk ¼,DlVMsa Ms jhfyt e½sa 11- iSjkflVkekys $ lQs bs u $ iRz ;ds vfyfir xkys h e sa % iSjkflVkekys 1 xkys h eSll Z ck;kds es 2-57 Qus hyQs jhu $ vkbiZ h 500 fexzk] lQs bs u ¼,ugkbMZ ªksl½ QkekZL;wfVdYl fMQus hgkbMZ ªekbu xkys h vkbiZ h 30 fexzk- QsuhyQs jhu buMLVªht fy- gkbMZ ªksDyksjkbM vkbiZ h 5 fexzk] fMQus hgkbMZ ªekbu gkbMZ ªkDs yksjkbM vkbiZ h 25 fexzk- 12- jehizhy $ ,eykMs hfiu xkys h iRz ;ds vfyfir xkys h e sa % jehizhy vkbiZ h 1 xkys h eSll Z yfqiu fy- 4-11 5 fexkz-] ,eykMs hfiu cfslyVs vkbiZ h d s cjkcj ,eykMs hfiu 5 fexzk- 13- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z yfqiu fy-@eSll Z 10-87 xkys h e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ ;uw hdes ycs ksjVs kfsjt fy- gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 fexzk- eVs QkfseuZ gkbMZ ªksDyksjkbM vkbiZ h 1000 fexzk ¼lLVMsa Ms jhfyt Qkes Z e½sa 14- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z yfqiu fy-@eSll Z 9-62 xkys h e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ ;uw hdes ycs ksjVs kfsjt fy- gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 fexzk-] eVs QksfeZu ,plh,y 500 fexzk 15- jkts qoklVkfVu $ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z lkbukds es 13-37 dSIlyw ¼jkbs LVkj lhoh jkts qoklVkfVu dfSY'k;e ds cjkcj QkekZL;wfVdYl fy- 10@75½ jkts qoklVkfVu 10 fexzk- ¼IyVs l e½sa] @eSll Z ;uw hdes DyksfiMkxs zys fclYQVs d s cjkcj ycs ksjVs kfsjt fy- DyksfiMkxs zys 75 fexzk- ¼IyVs l e½sa 16- jkts qoklVkfVu $ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z lkbukds es 7-80 dSIlyw jkbs LVkj lhoh 20@75 jkslqoklVkfVu dSfY'k;e ds cjkcj QkekZL;wfVdYl fy- jkslqoklVkfVu 20 fexzk- ¼IyVs l e½sa] @eSll Z ;uw hdes DyksfiMkxs zys fclYQVs d s cjkcj ycs ksjVs kfsjt fy- DyksfiMkxs zys 75 fexzk- ¼IyVs l e½sa 17- fMDykQs us d bta sD’ku iRz ;ds fefy- e%sa fMDykQs us d lkfsM;e 1 fefy- eSll Z dSfMyk gYs Fkd;s j 13-71 vkbiZ h 75 fefy bta Ds 'ku fy- 18- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z lkbukds es 9-62 xkys h ¼bQhXyhu ,e½ e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl fy-@ gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 eSll Z eMs kQs kekZ fexzk-] eVs QksfeZu ,plh,y 500 fexzk 19- jkts qoklVkfVu$ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z thd,s e U; w Qkek Z 7-80 dSIlyw jkts qoklVkfVu dSfY'k;e vkbiZ h d s cjkcj @ eSll Z dSfMyk jkts qoklVkfVu 20 fexzk- ¼xzkuqysl e½sa] gYs Fkd;s j fy-10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] DyksfiMkxs zys fclYQVs d s cjkcj DyksfiMkxs zys 75 fexzk- ¼fQYe fyfir xkys h e½sa 20- jkts qoklVkfVu$ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z lkbukds es 7-80 dSIlyw ¼jkts Ms s lhoh 20½ jkts qoklVkfVu dfSY'k;e ds cjkcj QkekZL;wfVdYl fy-@ jkts qoklVkfVu 20 fexzk- ¼IyVs l e½sa] eSll Z ;wlhoh izk- fy- DyksfiMkxs zys fclYQVs d s cjkcj DyksfiMkxs zys 75 fexzk- ¼IyVs l e½sa 21- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z lkbukds es 9-62 xkys h e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl @eSll Z gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 ,eD;wj QkekZL;fwVdYl fexzk-] fy- eVs QksfeZu ,plh,y 500 fexzk ¼lLVMsa Ms jhfyt Qkes Z e½sa 22- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z lkbukds es 10-87 xkys h e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl@eSll Z gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 ,eD;wj QkekZL;fwVdYl fexzk-] fy- eVs QksfeZu ,plh,y 1000 fexzk ¼lLVMsa Ms jhfyt Qkes Z e½sa 23- eVs QksfeZu $ Xyheis hjhM $ iRz ;ds xkys h e%sa 1 xkys h eSll Z luXyk s 9-39 okXs yhckWl xkys h eVs QksfeZu ,plh,y 500 fexzk ¼lLVMsa QkekZL;wfVdYl izk- fy@ jhfyt Qkes Z e½sa] eSll Z buVkl Xyheis hjhM 2 fexzk-] okXs yhckWl 0-3 fexzk- QkekZL;wfVdYl fy- 24- iSjkflVkekys xkys h iRz ;ds xkys h e%sa iSjkflVkeksy vkbiZ h 1 xkys h eSll Z iwj s ,Ma gYs Fkd;s j 3-15 ¼bEeMs Ms jhfyt e½sa 300 fexzk-] izk- fy-@eSll Z iSjkflVkekys vkbiZ h ¼lLVMsa jhfyt e½sa LVªklus cqx Z 700 fexzk- QkekZL;wfVdYl fy- 25- ,lDs ykQs us d $ iSjkflVkekys iRz ;ds xkys h e%sa ,lDs ykQs us d vkbiZ h 100 1 xkys h eSll Z jhoizk QkWeyw 's ku 2-78 xkys h fexzk-] izk- fy-@eSll Z dSfMyk iSjkflVkekys vkbiZ h 325 fexzk- QkekZL;wfVdYl 26- jkts qoklVkfVu$ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z lkbukds es 13-37 dSIlyw jkts qoklVkfVu 10 fexzk-] DykfsiMkxs zys QkekZL;wfVdYl fy- 75 fexzk- @eSll Z dSfMyk QkekZL;wfVdYl fy- 27- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z lkbukds es 10-87 xkys h ¼bQhXyhu ,e 1000½ e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl fy-@ gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu eSll Z eMs kQs kekZ 20 fexzk-] eVs QksfeZu ,plh,y 1000 fexzk- 28- vkys eslkjVu $ ,eykMs hihu iRz ;ds fQYe fyfir xkys h e%sa 1 xkys h eSll Z lkbukds es 7-24 xkys h vkys eslkjVu eMs ksDlksfey vkbiZ h QkekZL;wfVdYl fy- @ 20 fexzk-] ,eykMs hihu cslyVs vkbiZ h d s tqous Vl gYs Fkd;s j fy- cjkcj ,eykMs hihu 5 fexzk- 29- Vys ehlkjVu $ esVkis zkys ys iRz ;ds fQYe fyfir xkys h e%sa 1 xkys h eSll Z ,dEl MªXl ,Ma 7-62 xkys h ¼,DlVu&chVk 25 fexzk½ Vys ehlkjVu vkbiZ h 40 fexzk-] QkekZL;wfVdYl fy- eVs kis zkys ys VkjVªkV s vkbiZ h 25 fexkz- @eSll Z Cy w Øksl ¼bvZ kj½ ycs ksjVs kfsjt izk- fy- 30- Vys ehlkjVu $ esVkis zkys ys iRz ;ds fQYe fyfir xkys h e%sa 1 xkys h eSll Z ,dEl MªXl ,Ma 9-16 xkys h ¼,DlVu&chVk 50 fexzk½ Vys ehlkjVu vkbiZ h 40 fexzk-] QkekZL;wfVdYl fy- eVs kis zkys ys VkjVªkV s vkbiZ h 50 fexzk- @eSll Z Cy w Øksl ¼bvZ kj½ ycs ksjVs kfsjt izk- fy- 31- okXs yhckWl $ Xyheis jkbM $ iRz ;ds vfyfir ck;y;s M Z xkys h e:sa 10 xkys h eSll Z foMa ykl ck;kVs ds 68-50 eSVQkfseuZ xkys h okXs yhckWl vkbiZ h 0-2 fexzk-] Xyheis jkbM izk- fy-@eSll Z tqous Vl¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11 vkbiZ h 1 fexzk-] eSVQkfseuZ ,plh,y gYs Fkd;s j fy- vkbiZ h 500 fexzk ¼,lvkj½ 32- ,VksjoklVkfVu $ iRz ;ds gkM Z tys kVkbu dSIlyw esa% 10 eSll Z lk;ukds es 83-94 DyksfiMkxs zys dSIlyw ¼,Vdkys ,VksjoklVkfVu dSfY'k;e d s cjkcj dSIlyw QkekZL;wfVdYl fy- lhoh 10 fexzk-½ ,VksjoklVkfVu ¼IySVl e½sa 10 fexzk-] @eSll Z ,fjLVk s DyksfiMkxs zys ¼IySVl e½sa 75 fexzk- QkekZL;wfVdYl izk- fy- 33- okXs yhckWl $ Xyheis jkbM $ iRz ;ds vfyfir ck;y;s M Z xkys h e:sa 1 xkys h eSll Z foMa ykl ck;kVs ds 8-68 eSVQkfseuZ xkys h okXs yhckWl vkbiZ h 0-2 fexzk-] Xyheis jkbM izk- fy-@eSll Z tqous Vl vkbiZ h 2 fexzk-] eSVQkfseuZ ,plh,y gYs Fkd;s j fy- vkbiZ h 500 fexzk ¼,lvkj½ 34- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z foMa ykl ck;kVs ds 9-62 xkys h ¼Vus Ýs kus ,e½ e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ fy-@eSll Z ,CckVs bfaM;k gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 fy- fexzk-] eVs QksfeZu ,plh,y 500 fexzk- ¼,lvkj½ 35- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z foMa ykl ck;kVs ds 10-87 xkys h ¼Vus Ýs kus ,e QkVs ½Z e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ fy-@eSll Z ,CckVs bfaM;k gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 fy- fexzk-] eVs QksfeZu ,plh,y 1000 fexzk- ¼,lvkj½ 36- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe vfyfir ck;y;s M Z xkys h 1 xkys h eSll Z lk;ukds es 9-62 xkys h ¼Vk;fVu ,e½ e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ QkekZL;wfVdYl fy- gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 @eSll Z okWdgkMVZ fy- fexzk-] eVs QksfeZu ,plh,y 500 fexzk- ¼,DlVMsa jhfyt e½sa 37- VØs ksfyel dSIlyw iRz ;ds gkM Z tys kVkbu dSIlyw esa% 1 dSIlyw eSll Z ,eD;wj 10-82 VØs kfsyel vkbiZ h 0-25 fexzk- dSIlyw QkekZL;wfVdYl fy- 38- Vys felkjVu $ ,EykMs hfiu iRz ;ds fQYe vfyfir e%sa Vys felkjVu 10 xkys h eSll Z t-sd-s fiVza 106-05 xkys h vkbiZ h 80 fexzk-] iSDl@eSll Z eus dkbMa ,EykMs hfiu cslhyVs vkbiZ h 5 fexzk- Qkek Z fy- 39- Vys felkjVu $ ,EykMs hfiu iRz ;ds fQYe vfyfir e%sa Vys felkjVu 1 xkys h eSll Z lu Qkek Z 6-90 xkys h ¼fVxkVys ,,e 40½ vkbiZ h 40 fexzk-] ycs ksjVs kfsjt fy- ,EykMs hfiu cslhyVs vkbiZ h 5 fexzk- d s cjkcj ,EykMs hfiu 5 fexzk- 40- lfsQDlhe $ vkS¶yksDlklhu iRz ;ds fQYe fyfir xkys h e%sa 1 xkys h eSll Z Fkvs kus 9-46 xkys h ¼juhDlhe Iyl½ lfsQDlhe VªhgkbMªVs d s cjkcj lfsQDlhe QkekZL;wfVdYl fy- ,ugkbMªksl vkbiZ h 200 fexzk-] @eSll Z lu vkS¶yksDlklhu vkbiZ h 200 fexzk- QkekZL;wfVdYl buMLVªh,y fy- 41- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe fyfir ck;y;s M Z xkys h 1 xkys h eSll Z izslkbt des hQkek Z 9-62 xkys h ¼Xy;s iV s ,e½ e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ izk- fy-@eSll Z Ýkudk s gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 bfaM;k QkekZL;fwVdYl fexzk-] izk- fy- eVs QksfeZu ,plh,y 500 fexzk- 42- Vus fsyXyhiVhu $ eVs QksfeuZ iRz ;ds fQYe fyfir ck;y;s M Z xkys h 1 xkys h eSll Z izslkbt des hQkek Z 10-87 xkys h ¼Xy;s iV s ,e QkVs ½Z e:sa Vus fsyXyhiVhu gkbMZ ªkcs zkes kbMZ izk- fy-@eSll Z Ýkudk s gkbMZ ªVs d s cjkcj Vus fsyXyhiVhu 20 bfaM;k QkekZL;fwVdYl fexzk-] izk- fy- eVs QksfeZu ,plh,y 1000 fexzk- 43- Xyes hijkbM $ eSVQkfseuZ iRz ;ds vfyfir ck;y;s M Z xkys h e:sa 1 xkys h eSll Z buofsal;k 5-69 xkys h ¼ftXyhe&,e 1 QkVs ½Z Xyes hijkbM vkbiZ h 1 fexzk-] eSVQkfseuZ gYs Fkd;s j izk- fy- @ xkys h gkbMªkDs ykMs s Z vkbiZ h 1000 fexzk- eSll Z ,QMhlh fy-12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 44- Xyes hijkbM $ eSVQkfseuZ iRz ;ds vfyfir ck;y;s M Z xkys h e(sa 1 xkys h eSll Z buofsal;k 7-19 xkys h ¼ftXyhe&,e 2 QkVs ½Z Xyes hijkbM vkbiZ h 1 fexzk-] eSVQkfseuZ gYs Fkd;s j izk- fy- @ gkbMªkDs ykMs s Z vkbiZ h 1000 fexzk- eSll Z ,QMhlh fy- 45- fMDykQs us d bta sD'ku iRz ;ds fefy- e%sa fMDykQs us d lkfsM;e 1 fefy- eSll Z tk;Ml gYs Fkd;s j 13-71 vkbiZ h 75 fexzk-@fefy- fy- 46- MksDlk:s fcflu ¼ixs yfsVM iRz ;ds fefy- e%sa MksDlk:s fcflu ,plh,y 1 fefy- eSll Z ukVdk s Qkek Z fy- 694-29 fyikslkes ky½ bta Ds ’ku 2 fexzk- ¼isxyfsVM fyikslkes ky½ okVj QkWj bta Ds ’ku 47- Vys felkjVu $ buMkikekbM iRz ;ds vfyfir ck;y;s M Z xkys h e:sa 1 xkys h eSll Z foMa ykl ck;kVs ds 8-48 xkys h Vys felkjVu vkbiZ h 40 fexzk- izk- fy-@eSll Z eus dkbMa buMkikekbM vkbiZ h 1-5 fexzk- Qkek Z fy- 48- iSjkflVkekys $ eVs QksfeuZ iRz ;ds 5 fefy- e%sa iSjkflVkekys 1 fefy- eSll Z ,dEl MªXl ,Ma 0-57 ,flM bta Ds 'ku ¼tkbMZ kys &ih 250 fexzk- eVs QksfeuZ ,flM 100 fexzk- QkekZL;wfVdYl fy-@ Mh,l½ eSll Z tus cqjdV QkekZL;wfVdYl fy- 49- iSjkflVkekys $ iRz ;ds 5 fefy e%sa iSjkflVkekys 1 fefy- eSll Z jys Dl 0-57 Qus hyÝs hu $ DyksjQus hjkekbu 125 fexzk-] QkekZL;wfVdYl fy-@ $lksfM;e lkbVªsV $ eus Fkkys Qus hyÝs hu gkbMªkDs yksjkbM vkbiZ h eSll Z exs uVs ycs l izk- bta Ds 'ku 5 fexzk-] DyksjQus hjkekbu eys h,V vkbiZ h fy- 0-5 fexzk-] lkfsM;e lkbVªVs vkbiZ h 60 fexzk-] eus Fkkys vkbiZ h 1 fexzk- 50- ,VksjoklVkfVu $ DyksfiMkxs zys iRz ;ds gkM Z tys kVkbu dSIlyw esa% 10 eSll Z foMa ykl ck;kVs ds 83-94 dSIlyw ¼,Vkds ksj lhoh½ ,VksjoklVkfVu dSfY'k;e d s cjkcj dSIlyw izk- fy-@eSll Z Mk- ,VksjoklVkfVu ¼fQYe fyfir xkys h e½sa jMs M~ ht ycs ksjkVksfjt fy- 10 fexzk-] DykfsiMksxyzs fclYQVs d s cjkcj DyksfiMkxs yzs 75 fexzk- ¼iRz ;ds 2 fQYe fyfir 37-5 fexzk- xkys h e½sa 51- VØkfsyel dSIlyw - iRz ;ds gkM Z tys kVkbu dISlyw e%sa 1 dSIlyw eSll Z buVkl 10-82 VØkfsyel ifzseDl ¼20½ d s cjkcj QkekZL;wfVdYl fy- VØkfsyel vkbiZ h 0-25 fexzk- 52- ,VksjoklVkfVu $ DyksfiMkxs zys iRz ;ds dSIlyw e%sa ,VksjoklVkfVu 10 eSll Z ekbØk s ycs - 83-94 dSIlyw ¼,okl 10 xkYs M½ dSfY’k;e d s cjkcj ,VksjoklVkfVu dSIlyw ¼fQYe fyfir xkys h e½sa 10 fexzk- DyksfiMkxs zys fclYQVs d s cjkcj DyksfiMkxs zys 75 fexzk- ¼iRz ;ds 2 fQYe fyfir 37-5 fexzk- xkys h es½a 53- ,VksjoklVkfVu $ DyksfiMkxs zys iRz ;ds dSIlyw e%sa ,VksjoklVkfVu 10 eSll Z ekbØk s ycs - 83-94 dSIlyw ¼,okl 10 xkYs M½ dSfY'k;e d s cjkcj ,VksjoklVkfVu dSIlyw ¼fQYe fyfir xkys h e½sa 10 fexzk-] DyksfiMkxs zys fclYQVs d s cjkcj DyksfiMkxs zys 75 fexzk- ¼iRz ;ds 2 fQYe fyfir 37-5 fexzk- xkys h es½a 54- Xyes hijkbM $ eSVQkfseuZ iRz ;ds vfyfir ck;y;s M Z xkys h e(sa 1 xkys h eSll Z ekbØk s ycs - 2-22 xkys h ¼MkbijkbM ,e 0-5½ Xyes hijkbM vkbiZ h 0-5 fexzk-] eSVQkfseuZ ,plh,y vkbiZ h 500 fexzk- 55- Vys hfelkjVu $ iRz ;ds vfyfir xkys h e(sa Vys hfelkjVu 1 xkys h eSll Z lu Qkek Z 7-16 gkbMªkDs yksjkFs kkbtkbM xkys h vkbiZ h 40 fexzk-] gkbMªksDyksjksFkkbtkbM ycs ksjkVkfsjt fy- ¼fVxkyVs ,p 40½ vkbiZ h 12-5 fexzk- 56- Vys hfelkjVu $ iRz ;ds vfyfir xkys h e(sa Vys hfelkjVu 1 xkys h eSll Z lu Qkek Z 11-12 gkbMªkDs yksjkFs kkbtkbM xkys h vkbiZ h 40 fexzk-] gkbMªksDyksjksFkkbtkbM ycs ksjkVkfsjt fy- ¼fVxkyVs ,p 80½ vkbiZ h 12-5 fexzk- 57- Vys hfelkjVu $ ,EykMs hfiu iRz ;ds vfyfir xkys h e(sa Vys hfelkjVu 1 xkys h eSll Z lu Qkek Z 7-48 xkys h ¼fVxkyVs ,,e,p 40½ vkbiZ h 40 fexzk-] ,EykMs hfiu csl,yVs ycs ksjkVkfsjt fy- vkbiZ h d s cjkcj ,EykMs hfiu 5 fexzk-] gkbMªkDs yksjkFs kkbtkbM vkbiZ h 12-5 fexzk-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13 58- Vys hfelkjVu $ ,EykMs hfiu iRz ;ds vfyfir xkys h e(sa Vys hfelkjVu 10 xkys h eSll Z lu Qkek Z 117-83 xkys h ¼fVxkyVs ,,e,p 80½ vkbiZ h 80 fexzk-] ,EykMs hfiu csl,yVs ycs ksjkVkfsjt fy- vkbiZ h d s cjkcj ,EykMs hfiu 5 fexzk-] gkbMªkDs yksjkFs kkbtkbM vkbiZ h 12-5 fexzk- 59- lkQs kslcqohj $oys ikVklohj iRz ;ds fQYe fyfir xkys h e%sa 28 xkys h eSll Z gVs ªk s ycs fy- 15625-00 xkys h lkQs kslcqohj 400 fexzk-] oys ikVklohj @eSll Z ,eD;wj 100 fexzk- QkekZL;wfVdYl fy- 60- efsFkySifzsM,fulkys kus bta Ds ’ku iRz ;ds okW;y e%as efsFkySifzsM,fulkys kus 1 okW;y eSll Z ,D;wvk foVk,s 228-44 lkfsM;e lqlkbuVs ;,w lih d s cjkcj ycs ksjkVkfsjt@eSll Z efsFkyiS fzsM,fulkys kus 125 fexzk- Dykjhl butsDVcs y fy- 61- efsFkySifzsM,fulkys kus bta Ds 'ku iRz ;ds okW;y e%as efsFkySifzsM,fulkys kus 1 okW;y eSll Z ,D;wvk foVk,s 469-76 lkfsM;e lqlkbuVs ;,w lih d s cjkcj ycs ksjkVkfsjt@eSll Z efsFkyiS fzsM,fulkys kus 500 fexzk- Dykjhl butsDVcs y fy- 62- efsFkySifzsM,fulkys kus bta Ds 'ku iRz ;ds okW;y e%as efsFkySifzsM,fulkys kus 1 okW;y eSll Z ,D;wvk foVk,s 782-78 lkfsM;e lqlkbuVs ;,w lih d s cjkcj ycs ksjkVkfsjt@eSll Z efsFkyiS fzsM,fulkys kus 1000 fexzk- Dykjhl butsDVcs y fy- 63- ckVs hZjys bta Ds 'ku iRz ;ds okW;y e%sa ckVs htZ kfsec vkbiZ h 3-5 1 okW;y eSll Z fjyk;al ykbQZ 12500-00 fexzk bta sD’ku lkbal izk- fy- uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;½w ds rgr mi;qZDr nh xbZ lkj.kh d s LrHa k ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsxa As ¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LrHa k ¼6½ esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM + ldr s gSAa ¼x½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh d s LrHa k ¼6½ es a fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlfwpr fofufeZfr;ks a d s iSdksa d s fy, [kqnjk ewY; fu/kkZfjr djAsa fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klpw uk dh rkjh[k l s ,d eYw ; lpw h ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djAsa ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 ¼4½ ds mic/a kksa ds vuqlkj izR;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke'kZ ds bPNqd fdlh O;fDr ds fy, igqpa vklku gks] ogka mlds fdlh lgtn`'; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dks lia znf'kZr djxs kA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgkuas s vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 d s rgr vuqc) ewY; fu/kkZj.k@l'a kk/s ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklfaxd fof/k;k@sa fu;eksa ds vUrxZr tSlk fd dUs nzh;@jkT; ykblfslax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk eUs ;wQDs pfjxa ykblsal eta wjh ds rgr lca fa/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼p½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds vuqlpw h II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjikVs Z izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dkbs Z fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lpw uk ,uihih, dks voxr djk;sxkA blds lEcU/k eas vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls de ls de N% eghus igys lpw h II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼N½ fofuekZrk ;k foi.ku dEiuh] mijkDs r fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 d s izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼t½ bl vkn's k esa mijkDs r lkj.kh ds LrHa k ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;k sa ds iSdks a dh [kqnjk eYw ; fu;r gksus ds ifj.kkeLo#i]vkn's k tks fd bl vkn's k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxAs [dk-a l-a@183@51@2017@,Q@Qk- la0 8¼51½@2017@Mhih@,uihih,&fMoh-II] cythr flga ] lgk;d fun's kd14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ORDER New Delhi, the 18th December, 2017 S.O. 3915(E).— In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. Name of the Strength Unit Manufacturer & Retail No. Scheduled Marketing Company Price Formulation / Brand (Rs.) Name 1. Ferrous Ascorbate + Each film coated tablet contains: 1 Tablet M/s. Tirupati 3.63 Folic Acid + Ferrous Ascorbate eq. to Elemental Iron Medicare Limited / Cyanocobalamin + 100mg, M/s. Pfizer Limited Zinc Sulphate Folic Acid IP 1.5mg, Monohydrate tablet Cyanocobalamin IP 15 mcg, (Autrin - XT) Zinc Sulphate Monohydrate IP eq. to Elemental Zinc 22.5mg 2. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s. Aeon 13.37 Clopidogrel Capsule Rosuvastatin Calcium IP eq. to Rosuvastatin Formulation Pvt. Ltd. (Roseday CV 10) (As granules) 10mg, / M/s. USV Private Clopidogrel Bisulphate IP eq. to Limited Clopidogrel (As a film coated tablet) 75mg 3. Teneligliptin + Each uncoated bilayered tablets contains: 1 Tablet M/s. Glenamark 10.87 Metformin tablet Teneligliptin Hydrobromide hydrate eq. to Pharmaceuticals Ltd. / (Ten20 M 1000) Teneligliptin 20mg, M/s. Centaur Metformin HCL 1000mg (as extended Pharmaceuticals Pvt. release) Ltd. 4. Clobetasol + Each gm contains: 1 GM M/s. Mankind 2.92 Clotrimazole + Clobetasol Propionate IP 0.05%w/w, Pharma Ltd./ M/s. Neomycin Sulphate Clotrimazole IP 1.00% w/w, Pharma Force Lab. Cream Neomycin Sulphate IP 0.50%w/w 5. Moxifloxacin + Each Coated Sustained Release tablet 1 Tablet M/s. Akums Drugs 33.05 Cefixime Tablets contains: Moxifloxacin Hydrochloride BP and Pharmaceuticals (Moximac Plus) eq. to Moxifloxacin 400mg, Ltd. / M/s. Macleods Cefixime IP (as trihydrate) eq. to Ahydrous Pharmaceuticals Ltd. Cefixime 400mg 6. Moxifloxacin + Each Coated Sustained Release tablet 1 Tablet M/s. Akums Drugs 33.05 Cefixime Tablets contains: Moxifloxacin Hydrochloride BP and Pharmaceuticals (Macflox Plus) eq. to Moxifloxacin 400mg, Ltd. / M/s. Macleods Cefixime IP (as trihydrate) eq. to Ahydrous Pharmaceuticals Ltd. Cefixime 400mg 7. Tramadol + Each Film Coated tablet contains: 1 Tablet M/s. Anglo French 5.57 Paracetamol Tablet Tramadol Hydrochloride IP 37.5mg, Drugs & Industries Paracetamol IP 325mg Ltd. 8. Rosuvastatin + Each film coated bilayered tablet contains: 1 Tablet M/s. Safetab Life 9.97 Aspirin + Rosuvastatin Calcium IP eq. to Science / M/s. Intas Clopidogrel Tablet Rosuvastatin 10mg, Pharmaceuticals Aspirin IP 75mg, Limited Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg 9. Teneligliptin + Each uncoated bilayered tablets contains: 1 Tablet M/s. Synokam 9.62 Metformin Tablet Teneligliptin Hydrobromide hydrate eq. to Pharma limited/ M/s.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15 Teneligliptin 20mg, Cadila Pharmceuticals Metformin HCL 500mg (as extended Ltd. release) 10. Teneligliptin + Each uncoated bilayered tablets contains: 1 Tablet M/s. Synokam 10.87 Metformin Tablet Teneligliptin Hydrobromide hydrate eq. to Pharma limited/ M/s. Teneligliptin 20mg, Cadila Pharmceuticals Metformin HCL 1000mg (as extended Ltd. release) 11. Paracetamol + Each uncoated tablet contains: 1 Tablet M/s. Biochem 2.57 Caffeine + Paracetamol IP 500mg, Pharmaceutical Phenylephrine + Caffeine (Anhydrous) IP 30mg, Industries Ltd. Diphenhydramine Phenylephrine Hydrochloride IP 5mg, Tablet Diphenhydramine Hydrochloride IP 25mg 12. Ramipril + Each uncoated tablet contains: 1 Tablet M/s. Lupin Limited 4.11 Amlodipine Tablet Ramipril IP 5mg, Amlodipine Besilate IP eq. to Amlodipine 5mg 13. Teneliglitptin + Each Film uncoated bilayer tablet contains: 1 tablet M/s. Lupin Limited / 10.87 Metformin Tablet Teneliglitptin Hydrobromide Hydrate 20mg M/s. Unichem eq. to Tenegliptin 20mg, Laboratories Ltd. Metformin Hydrochloride IP 1000mg (In Sustained Release form) 14. Teneliglitptin + Each uncoated bilayer tablet contains: 1 Tablet M/s. Lupin Limited / 9.62 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to M/s. Unichem Teneligliptin 20mg, Laboratories Ltd Metformin Hydrochloride IP 500mg 15. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s. Synokem 13.37 Clopidogrel Capsule Rosuvastatin Calcium IP eq. to Pharmaceuticals Ltd. / (Roistar CV 10/75) Rosuvastatin 10mg (As Pellets), M/s. Unichem Clopidogrel Bisulphate IP eq. to Laboratories Ltd. Clopidogrel 75mg (as Pellets) 16. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s. Synokem 7.80 Clopidogrel Rosuvastatin Calcium IP eq. to Pharmaceuticals Ltd. / Capsule (Roistar Rosuvastatin 20mg (As Pellets), M/s. Unichem CV 20/75) Clopidogrel Bisulphate IP eq. to Laboratories Ltd. Clopidogrel 75mg (as Pellets) 17. Diclofenac Injection Each ml contains: 1 ML M/s. Cadila 13.71 Diclofenac Sodium IP 75mg Injection Healthcare Ltd. 18. Teneligliptin + Each uncoated Bilayered tablet contains: 1 Tablet M/s. Synokem 9.62 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Pharmaceuticals Ltd. / (EFIGLIN M) Teneligliptin 20mg, M/s. MedoPharm, Metformin HCl 500mg 19. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s. GKM New 7.80 Clopidogrel Capsule Rosuvastatin Calcium IP eq. to Pharma / M/s. Cadila Rosuvastatin 20mg (As granules), Healthcare Ltd. Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as to film coated tablets) 20. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s. Synokem 7.80 Clopidogrel Capsule Rosuvastatin Calcium IP eq. to Rosuvastatin Pharmaceuticals Ltd. / (Roseday CV 20) (As Pellets) 20mg, M/s. USV Pvt. Ltd, Clopidogrel Bisulphate IP eq. to Clopidogrel (As Pellets ) 75mg 21. Teneligliptin + Each uncoated bilayer tablet contains: 1 Tablet M/s. Synokem 9.62 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Pharmaceuticals Ltd. / Teneligliptin 20mg, M/s. Emcure Metformin HCL 500mg (as sustained Pharmaceuticals Ltd. release) 22. Teneligliptin + Each uncoated bilayer tablet contains: 1 Tablet M/s. Synokem 10.87 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Pharmaceuticals Ltd. /16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Teneligliptin 20mg, M/s. Emcure Metformin HCL 1000mg (as sustained Pharmaceuticals Ltd. release) 23. Metformin + Each tablet contains: 1 Tablet M/s. Sunglow 9.39 Glimepiride + Metformin HCL 500mg Pharmaceuticals Pvt. Voglibose Tablet (as sustained release form), Glimepiride Ltd. / M/s. Intas 2mg, Pharmaceuticals Ltd. Voglibose 0.3mg 24. Paracetamol Tablet Each tablet contains: 1 Tablet M/s. Pure and Cure 3.15 Paracetamol IP (as Immediate Release) Healthcare Pvt. Ltd. / 300mg, M/s. Strassenburg Paracetamol IP (as Sustained Release) Pharmaceuticals Ltd. 700mg 25. Aceclofenac + Each Tablet contains: Aceclofenac IP 1 Tablet M/s. Rivpra 2.78 Paracetamol Tablet 100mg, Formulation Pvt. Ltd. Paracetamol IP 325mg / M/s. Cadila Pharmaceuticals Ltd. 26. Rosuvastatin + Each Hard gelatin capsule contains: 1 Capsule M/s. Synokem 13.37 Clopidogrel Capsule Rosuvastatin 10mg, Pharmaceuticals Ltd. / Clopidogrel 75mg M/s. Cadila Pharmaceuticals Ltd. 27. Teneligliptin + Each uncoated Bilayered tablet contains: 1 Tablet M/s. Synokem 10.87 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Pharmaceuticals Ltd. / (EFIGLIN M 1000) Teneligliptin 20mg, M/s. MedoPharm Metformin Hydrochloride IP 1000mg (as Sustained Release form) 28. Olmesartan + Each film coated tablet contains: 1 Tablet M/s. Synokem 7.24 Amlodipine Tablet Olmesartan Medoxomil IP 20mg, Pharmaceuticals Ltd. Amlodipine Besylate IP eq. to Amlodipine / M/s. Zuventus 5mg, Healthcare Limited 29. Telmisartan + Each film coated tablet contains: 1 Tablet M/s. Akums Drugs 7.62 Metoprolol Tablet Telmisartan IP 40mg, and Pharmaceuticals (Xstan-Beta 25mg) Metoprolol Tartrate IP 25mg (ER) Ltd. / M/s. Blue Cross Laboratories Pvt. Ltd. 30. Telmisartan + Each film coated tablet contains: 1 Tablet M/s. Akums Drugs 9.16 Metoprolol Tablet Telmisartan IP 40mg, and Pharmaceuticals (Xstan-Beta 50mg) Metoprolol Tartrate IP 50mg (ER) Ltd. / M/s. Blue Cross Laboratories Pvt. Ltd. 31. Voglibose + Each uncoated bilayered tablet contains: 10 Tablets M/s. Windlas Biotech 68.50 Glimepride + Voglibose IP 0.2mg, Glimepride IP 1mg, Pvt. Ltd. / M/s. Metformin Tablet Metformin HCL IP 500mg (SR) Zuventus Healthcare Limited 32. Atorvastatin + Each hard gelatin capsule contains: 10 M/s. Synokem 83.94 Clopidogrel Atorvastatin Calcium eq. to Atorvastatin (as Capsule Pharmaceuticals Ltd. / Capsules (Atchol pellets) 10mg, M/s. Aristo CV 10mg) Clopidogrel (as pellets) 75mg. Pharmaceuticals Pvt. Ltd. 33. Voglibose + Each uncoated bilayered tablet contains: 1 Tablet M/s. Windlas Biotech 8.68 Glimepride + Voglibose IP 0.2mg, Glimepride IP 2mg, Pvt. Ltd. /M/s. Metformin Tablet Metformin Hydrochloride IP 500mg (SR) Zuventus Healthcare Limited 34. Teneligliptin + Each uncoated bilayered tablet contains: 1 Tablet M/s. Windlas Biotech 9.62 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Limited / M/s. Abbott (Tenephron M) Teneligliptin 20mg, India Limited Metformin Hydrochloride 500mg (SR) 35. Teneligliptin + Each uncoated bilayered tablet contains: 1 Tablet M/s. Windlas Biotech 10.87 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Limited / M/s. Abbott (Tenephron M Teneligliptin 20mg, India Limited Forte) Metformin HCl 1000mg (SR)¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 17 36. Teneligliptin + Each uncoated bilayered tablet contains: 1 Tablet M/s. Synokem 9.62 Metformin Tablet Teneligliptin Hydrobromide hydrate eq. to Pharmaceuticals Ltd. / (TYTIN M) Teneligliptin 20mg, M/s. Wockhardt Ltd. Metformin Hydrochloride 500mg (as extended release) 37. Tacrolimus Capsule Each Hard gelatin capsule contains: 1 Capsule M/s. Emcure 10.82 Tacrolimus IP 0.25mg Pharmaceuticals Ltd, 38. Telmisartan + Each uncoated bilayer tablet Contains: 10 Tablet M/s. J. K. Print Packs 106.05 Amlodipine Tablet Telmisartan IP 80mg, / M/s. Mankind Amlodipine Besilate IP 5mg Pharma Ltd. 39. Telmisartan + Each film coated tablet contains: 1 Tablet M/s. Sun Pharma 6.90 Amlodipine Tablet Telmisartan IP 40mg, Laboratories Limited (Tigatel AM 40) Amlodipine Besylate IP eq. to Amlodipine 5mg 40. Cefixime + Each film coated tablet contains: 1 Tablet M/s. Theon 9.46 Ofloxacin Tablet Cefixime Trihydrate eq. to Cefixime Pharmaceuticals (Ranixime Plus) Anhydrous IP 200mg, Ofloxacin IP 200mg Limited / M/s. Sun Pharmaceutical Industrial Limited 41. Teneligliptin + Each film coated tablet contains: 1 Tablet M/s. Precise 9.62 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Chemipharma Pvt. (Glypte M) Teneligliptin 20mg, Ltd. / M/s. Franco Metformin Hydrochloride 500mg India Pharmaceuticals Private Limited 42. Teneligliptin + Each film coated tablet contains: 1 Tablet M/s. Precise 10.87 Metformin Tablet Teneligliptin Hydrobromide Hydrate eq. to Chemipharma Pvt. (Glypte M Forte) Teneligliptin 20mg, Ltd. / M/s. Franco Metformin Hydrochloride 1000mg India Pharmaceuticals Private Limited 43. Glemipiride + Each uncoated bilayered tablet contains: 1 Tablet M/s. Inventia 5.69 Metformin Tablet Glemipiride IP 1mg, Healthcare Pvt. Ltd. / (Ziglim – M1 Forte) Metformin Hydrochlorde IP 1000mg (as SR M/s. FDC Limited form) 44. Glemipiride + Each uncoated bilayered tablet contains: 1 tablet M/s. Inventia 7.19 Metformin Tablet Glimepiride IP 2mg, Healthcare Pvt. Ltd. / (Ziglim – M2 Forte) Metformin Hydrochlorde IP 1000mg (as SR M/s. FDC Limited form) 45. Diclofenac Injection Each ml contains: 1 ml M/s. Zydus 13.71 Diclofenac Sodium IP 75mg/ml Healthcare Ltd. 46. Doxorubicin Each ml contains: 1 ml M/s. Natco Pharma 694.29 (Pegylated Doxorubicin HCL 2mg (Pegylated Ltd. Liposomal) Liposomal) water for Injection Injection 47. Telmisartan + Each uncoated bilayered tablet contains: 1 Tablet M/s. Windlas Biotech 8.48 Indapamide Tablet Telmisartan IP 40mg Pvt. Ltd. / M/s. Indapamide IP 1.5mg Mankind Pharma Ltd. 48. Paracetamol + Each 5ml contains: 1 ml M/s. Akums Drugs & 0.57 Mefenamic Acid Paracetamol 250mg Mefenamic Acid Pharmaceuticals Ltd. / Injection (Zydol-P 100mg M/s. Jenburkt DS) Pharmaceuticals Ltd. 49. Paracetamol + Each 5ml contains: Paracetamol 125mg 1 ml M/s. Relax 0.57 Phenylephrine + Phenylephrine Hydrochloride IP 5mg, Pharmaceuticals Ltd. / Chlorpheniramine + Chlorpheniramine Maleate IP 0.5mg, M/s. Magnet Labs Sodium Citrate + Sodium Citrate IP 60mg, Pvt. Ltd. Menthol Injection Menthol IP 1mg 50. Atorvastatin + Each hard gelatin capsule contains: 10 M/s. Windlas Biotech 83.94 Clopidogrel Capsule Atorvastatin Calcium IP eq. to Atorvastatin Capsule Pvt. Ltd. / M/s. Dr.18 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (Atocor CV) 10mg (As film coated tablet), Reddy’s Laboratories Clopidogrel Bisulphate IP eq. to Ltd. Clopidogrel 75mg (As 2 film coated 37.5mg each tablet) 51. Tacrolimus Capsule Each hard gelatin capsule contains: 1 Capsule M/s. Intas 10.82 Tacrolimus premix (20%) eq. to Tacrolimus Pharmaceuticals Ltd. IP 0.25mg 52. Atorvastatin + Each capsule contains: 10 M/s. Micro Lab. Ltd. 83.94 Clopidogrel Capsule Atorvastatin Calcium IP eq. to Atorvastatin Capsule (Avas 10 Gold) 10mg (As film coated tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As 2 film coated 37.5mg each tablet) 53. Atorvastatin + Each capsule contains: 10 M/s. Micro Lab. Ltd. 83.94 Clopidogrel Capsule Atorvastatin Calcium IP eq. to Atorvastatin Capsule (Astin 10 Gold) 10mg (As film coated tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As 2 film coated 37.5mg each tablet) 54. Glimepiride + Each uncoated bilayered tablet contains: 1 Tablet M/s. Micro Lab. Ltd. 2.22 Metformin Tablet Glimepiride IP 0.5mg, (DIAPRIDE M 0.5) Metformin Hydrochloride IP 500mg (SR) 55. Telmisartan + Each uncoated tablet contains: 1 Tablet M/s. Sun Pharma 7.16 Hydrochlorothiazide Telmisartan IP 40mg, Hydrochlorothiazide Laboratories Ltd. Tablet (Tigatel H IP 12.5mg 40) 56. Telmisartan + Each uncoated tablet contains: 1 Tablet M/s. Sun Pharma 11.12 Hydrochlorothiazide Telmisartan IP 80mg, Hydrochlorothiazide Laboratories Ltd. Tablet (Tigatel H IP 12.5mg 80) 57. Telmisartan + Each uncoated tablet contains: 1 Tablet M/s. Sun Pharma 7.48 Amlodipine Tablet Telmisartan IP 40mg, Amlodipine Besylate Laboratories Ltd. (Tigatel AMH 40) IP Eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg 58. Telmisartan + Each uncoated tablet contains: 10 Tablet M/s. Sun Pharma 117.83 Amlodipine Tablet Telmisartan IP 80mg, Amlodipine Besylate Laboratories Ltd. (Tigatel AMH 80) IP Eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg 59. Sofosbuvir + Each film coated tablet contains: 28 tablets M/s. Hetro Lab 15625.00 Velpatasvir Tablet S o f o s b u v i r 4 0 0 m g, Limited / M/s. Velpatasvir 100mg Emcure Pharmaceutical Limited 60. Methylprednisolone Each Vial contains: 1 Vial M/s. Aqua Vitoe 228.44 Injection Methylprednisolone Sodium Succinate USP. Laboratories / M/s. Eq. to Claris Injectable Methylprednisolone 125mg Limited, 61. Methylprednisolone Each Vial contains: 1 Vial M/s. Aqua Vitoe 469.76 Injection Methylprednisolone Sodium Succinate USP. Laboratories / M/s. Eq. to Claris Injectable Methylprednisolone 500mg Limited, 62. Methylprednisolone Each Vial contains: 1 Vial M/s. Aqua Vitoe 782.78 Injection Methylprednisolone Sodium Succinate USP. Laboratories / M/s. Eq. to Claris Injectable Methylprednisolone 1000mg Limited, 63. Bortezomib Each vial contains: 1 Vial M/s. Reliance Life 12500.00 Injection (BortiRel) Bortezomib IP 3.5mg Injection Sciences Pvt. Ltd.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 19 Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (h) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior tothe above said date of notification, stand(s) superseded [PN/183/51/2017/F /F. No. 8(51)/2017/D.P./NPPA-Div.-II ] BALJIT SINGH, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.